Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Photon upconversion crystals doped bacterial cellulose composite films as recyclable photonic bioplastics

  • Bharmoria, Pankaj|||0000-0001-6573-0475
  • Naimovičius, Lukas|||0000-0002-3358-4108
  • Abol-Fotouh, Deyaa|||0000-0003-4505-5534
  • Miroshnichenko, Mila
  • Lekavičius, Justas
  • De Luca, Gabriele|||0000-0003-3757-3761
  • Saeed, Umair|||0000-0001-7397-9123
  • Kazlauskas, Karolis
  • Candau, Nicolas|||0000-0002-1559-8696
  • Baronas, Pauliu
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Moth-Poulsen, Kasper|||0000-0003-4018-4927
Biopolymers currently utilized as substitutes for synthetic polymers in photonics applications are predominantly confined to linear optical color responses. Herein we expand their applications in non-linear optics by integrating with triplet-triplet annihilation photon upconversion crystals. A photon upconverting biomaterial is prepared by cultivating Pd(II) meso-tetraphenyl tetrabenzoporphine: 9,10-diphenyl anthracene (sensitizer: annihilator) crystals on bacterial cellulose hydrogel that serves both as host and template for the crystallization of photon upconversion chromophores. Coating with gelatin improves the material's optical transparency by adjusting the refractive indices. The prepared material shows an upconversion of 633 nm red light to 443 nm blue light, indicated by quadratic to linear dependence on excitation power density (non-linearly). Notably, components of this material are physically dis-assembled to retrieve 66 ± 1% of annihilator, at the end of life. Whereas, the residual clean biomass is subjected to biodegradation, showcasing the sustainability of the developed photonics material.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Priming Mesenchymal Stem Cells with Lipopolysaccharide Boosts the Immunomodulatory and Regenerative Activity of Secreted Extracellular Vesicles

  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Solé-Porta, Anna|||0000-0002-6129-4087
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Laffey, John|||0000-0002-1246-9573
  • Closa Autet, Daniel|||0000-0003-3797-3095
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Background: Mesenchymal stem cells (MSCs)-derived extracellular vesicles (EVs) have been proposed as an alternative to live-cell administration for Acute Respiratory Distress Syndrome (ARDS). MSC-EVs can be chiefly influenced by the environment to which the MSCs are exposed. Here, lipopolysaccharide (LPS) priming of MSCs was used as a strategy to boost the natural therapeutic potential of the EVs in acute lung injury (ALI). Methods: The regenerative and immunemodulatory effect of LPS-primed MSC-EVs (LPS-EVs) and non-primed MSC-EVs (C-EVs) were evaluated in vitro on alveolar epithelial cells and macrophage-like THP-1 cells. In vivo, ALI was induced in adult male rats by the intrapulmonary instillation of HCl and LPS. Rats (n = 8 to 22/group) were randomized to receive a single bolus (1 × 10 particles) of LPS-EVs, C-EVs, or saline. Lung injury severity was assessed at 72 h in lung tissue and bronchoalveolar lavage. Results: In vitro, LPS-EVs improved wound regeneration and attenuated the inflammatory response triggered by the P. aeruginosa infection, enhancing the M2 macrophage phenotype. In in vivo studies, LPS-EVs, but not C-EVs, significantly decreased the neutrophilic infiltration and myeloperoxidase (MPO) activity in lung tissue. Alveolar macrophages from LPS-EVs-treated animals exhibited a reduced expression of CXCL-1, a key neutrophil chemoattractant. However, both C-EVs and LPS-EVs reduced alveolar epithelial and endothelial permeability, mitigating lung damage. Conclusions: EVs from LPS-primed MSCs resulted in a better resolution of ALI, achieving a greater balance in neutrophil infiltration and activation, while avoiding the complete disruption of the alveolar barrier. This opens new avenues, paving the way for the clinical implementation of cell-based therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model

  • Solé-Porta, Anna|||0000-0002-6129-4087
  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Fernández Fernández, E.|||0000-0002-5823-2731
  • O'Sullivan, Andrew|||0000-0002-5434-1260
  • Giannoccari, Rossella
  • MacLoughlin, Ronan
  • Closa Autet, Daniel|||0000-0003-3797-3095
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Roig i Serra, Anna|||0000-0001-6464-7573
Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not demonstrated a reduction in ARDS-associated mortality. This is in part connected to the singularity of the pulmonary physiological barrier, which hampers drug delivery, specifically at distal areas. To this aim, the use of polymeric nanocarriers as a platform for the efficient delivery of therapeutics to the lungs by nebulization is introduced. Herein, poly(lactic-co-glycolic acid) (PLGA) nanocapsules (NCs) loaded with human serum albumin, as an inhalable nanotherapeutic are prepared. The production of stable NCs aerosols in the inhalable range is achieved using a commercial device, while the nanocarrier's physicochemical parameters are only minimally altered after nebulization. Importantly, in vivo studies with healthy and acute lung injury animals show that after inhalation, the NCs are homogeneously distributed throughout the lungs, arriving at the distal areas. The NCs are internalized by alveolar type II cells, avoiding macrophage-mediated lung clearance. These features make the PLGA NCs excellent vehicles for noninvasive pulmonary delivery, facilitating a ready-to-be-used nanomedicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bioengineered extracellular vesicles, future of precision medicine for sepsis

  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Solé-Porta, Anna|||0000-0002-6129-4087
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Closa Autet, Daniel|||0000-0003-3797-3095
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Sepsis is a syndromic response to infection and is frequently a final common pathway to death from many infectious diseases worldwide. The complexity and high heterogeneity of sepsis hinder the possibility to treat all patients with the same protocol, requiring personalized management. The versatility of extracellular vesicles (EVs) and their contribution to sepsis progression bring along promises for one-to-one tailoring sepsis treatment and diagnosis. In this article, we critically review the endogenous role of EVs in sepsis progression and how current advancements have improved EVs-based therapies toward their translational future clinical application, with innovative strategies to enhance EVs effect. More complex approaches, including hybrid and fully synthetic nanocarriers that mimic EVs, are also discussed. Several pre-clinical and clinical studies are examined through the review to offer a general outlook of the current and future perspectives of EV-based sepsis diagnosis and treatment.